Shopping Cart
- Remove All
 
Your shopping cart is currently empty
PAP-1 (5-(4-Phenoxybutoxy)psoralen) is a selective, orally active Kv1.3 blocker with an EC50 of 2 nM.

| Pack Size | Price | Availability | Quantity | 
|---|---|---|---|
| 2 mg | $57 | In Stock | |
| 5 mg | $81 | In Stock | |
| 10 mg | $138 | In Stock | |
| 25 mg | $307 | In Stock | |
| 50 mg | $547 | In Stock | |
| 100 mg | $578 | In Stock | |
| 200 mg | $827 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $92 | In Stock | 
| Description | PAP-1 (5-(4-Phenoxybutoxy)psoralen) is a selective, orally active Kv1.3 blocker with an EC50 of 2 nM.  | 
| Targets&IC50 |  Kv1.5 channel:45 nM (EC50), Kv1.3 channel:2 nM (EC50)  | 
| In vitro | PAP-1 blocks Kv1.3 in a use-dependent manner and acts by preferentially binding to the C-type inactivated state of the channel. PAP-1 exhibits 23-fold selectivity over Kv1.5 (EC50: 45 nM), and further displays 33- to 125-fold selectivity over all other Kv1-family channels [1, 2]. PAP-1 (2-100 nM; 30 minutes) suppresses the proliferation of CCR7-TEM cells (IC50: 10 nM) [1].  | 
| In vivo | PAP-1 (0.3-3 mg/kg; i.p.; thrice daily for 48 hours) prevents delayed type hypersensitivity (DTH) in Lewis rats [1].  | 
| Cell Research | Cell Line: CCR7-TEM cells (anti-CD3 Ab stimulated). Concentration: 2, 10, 25, 100 nM. Incubation Time: 30 minutes [1]  | 
| Animal Research | Animal Model: 9- to 11- week-old female Lewis rats. Dosage: I.P.; three times daily for 48 hours. Administration: 0.3, 1, 3 mg/kg [1]  | 
| Synonyms | 5-(4-Phenoxybutoxy)psoralen | 
| Molecular Weight | 350.36 | 
| Formula | C21H18O5 | 
| Cas No. | 870653-45-5 | 
| Smiles | O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1 | 
| Relative Density. | 1.269 | 
| Color | White | 
| Appearance | Solid | 
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (57.08 mM), Sonication is recommended.  H2O: Insoluble   | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.71 mM), Sonication is recommended.  Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table  | |||||||||||||||||||||||||||||||
DMSO 
  | |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.